Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

The investigators propose a phase II randomized-controlled study on using durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab, compared to induction chemotherapy followed by concurrent chemoradiation for previously untreated locoregionally advanced stage III to IVA NPC.

formalin-fixed paraffin-embedded
cisplatin
hysterectomy
bilateral oophorectomy
bilateral salpingectomy
  • 0 views
  • 19 Feb, 2024
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent chemoradiotherapy(CCRT) combined with nimotuzumab can improve the survival rate of high-risk patients and may provide new evidence for individualized comprehensive treatment of …

renal function test
concurrent radiochemotherapy
EGFR
epstein-barr virus dna
nimotuzumab
  • 4 views
  • 19 Feb, 2024
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

This is a prospective single-arm study of endoscopic resection (ER) following concurrent chemoradiotherapy for stage I esophageal squamous cell carcinoma, to find if the treatment combination is useful by assessing its safety and efficacy.

blood pregnancy test
metastasis
mucous membrane
esophageal carcinoma
endoscopic resection
  • 0 views
  • 19 Feb, 2024
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation.

urine test
secondary malignant neoplasm of liver
metastasis
hysterectomy
absolute neutrophil count
  • 0 views
  • 19 Feb, 2024
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.

squamous cell carcinoma of esophagus
measurable disease
camrelizumab
monoclonal antibodies
cisplatin
  • 0 views
  • 19 Feb, 2024
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer

The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.

adenocarcinoma
cisplatin
concurrent chemoradiation
adjuvant chemotherapy
cervical cancer
  • 0 views
  • 19 Feb, 2024
Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma

A Phase II trial to study the effectiveness and security of cisplatin concurrent chemoradiotherapy plus TIL versus cisplatin concurrent chemoradiotherapy only in treating patients with FIGO stage IIIA to IVA cervical carcinoma.

adenocarcinoma
cisplatin
cervical cancer
squamous cell carcinoma
adenosquamous carcinoma
  • 0 views
  • 19 Feb, 2024
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

The induction platinum-based chemotherapy may increase the neoantigen formation together with the chemoradiotherapy period. Starting durvalumab during the first chemotherapy session and continuing during the 6-week period of chemoradiotherapy could change and create the needed environment to increase the efficacy of durvalumab in this setting.

adenocarcinoma
rectal cancer
adjuvant therapy
adenocarcinoma of rectum
carcinoma in situ
  • 0 views
  • 19 Feb, 2024
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer

Standard chemoradiation, followed by surgery are standard treatment plan for patients suffering from pancreatic adenocarcinoma. Due to damage to the surrounding healthy tissue caused by standard radiation, this study uses a new type of radiation plan- pulsed low-dose rate (PLDR) radiation , in combination with chemotherapeutic drug, gemcitabine, given weekly …

adenocarcinoma
celiac
metastatic pancreatic cancer
gemcitabine
pancreatic adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

renal function test
karnofsky performance status
concurrent radiochemotherapy
cisplatin
metastasis
  • 0 views
  • 19 Feb, 2024